Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Has results × Advanced Cancer × Trastuzumab × Clear all

Sponsor

Conditions

Breast Neoplasms 208 Stomach Neoplasms 17 Neoplasm Metastasis 13 Breast Neoplasms, Male 13 Neoplasms 8 Esophageal Neoplasms 8 Brain Neoplasms 7 Inflammatory Breast Neoplasms 6 Colorectal Neoplasms 4 Adenocarcinoma Of Esophagus 4 Triple Negative Breast Neoplasms 3 Urologic Neoplasms 2 HER2-positive Breast Cancer 2 Gallbladder Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Intraductal, Noninfiltrating 2 Carcinoma, Ductal, Breast 2 Adenocarcinoma 2 Urinary Bladder Neoplasms 1 Solid Cancers 1 Rectal Neoplasms 1 Patient Preference 1 Patient Compliance 1 Osteitis Deformans 1 Neoplasm, Residual 1 Meningeal Neoplasms 1 Malignant Solid Neoplasm 1 Locally Advanced Breast Cancer 1 Lethal Congenital Contracture Syndrome 2 1 Hormone Receptor Positive Breast Cancer 1

Interventions

Nivolumab 7 linrodostat 3 Ipilimumab 3 relatlimab 2 Pemetrexed 2 tislelizumab 1 regorafenib 1 ralimetinib 1 p38 Mitogen-Activated Protein Kinases 1 figitumumab 1 efatutazone 1 abemaciclib 1 Vorinostat 1 Tamoxifen 1 Sunitinib 1 Ranitidine 1 Midazolam 1 LY2603618 1 LY2584702 1 Gemcitabine 1 Fulvestrant 1 Dasatinib 1 Crizotinib 1 Cetuximab 1 Carboplatin 1 BMS-813160 1 3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡